- Home
- FCNCP vs SRPT Comparison
FCNCP vs SRPT Comparison
Compare FCNCP & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FCNCP | SRPT |
|---|---|---|
| Founded | N/A | 1980 |
| Country | United States | United States |
| Employees | 18141 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 2.5B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | FCNCP | SRPT |
|---|---|---|
| Price | $21.24 | $20.03 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 28 |
| Target Price | N/A | ★ $25.40 |
| AVG Volume (30 Days) | 14.8K | ★ 3.2M |
| Earning Date | N/A | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,198,237,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $19.30 | $10.42 |
| 52 Week High | $22.86 | $67.47 |
Technical Indicators
Market Signals| Indicator | FCNCP | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 46.68 | 56.41 |
| Support Level | $20.82 | $16.38 |
| Resistance Level | $21.33 | $23.01 |
| Average True Range (ATR) | 0.24 | 1.20 |
| MACD | -0.02 | 0.62 |
| Stochastic Oscillator | 54.23 | 49.54 |
Price Performance
Historical ComparisonAbout FCNCP First Citizens BancShares Inc.
First Citizens BancShares Inc. is a Raleigh, N.C.-based financial holding company operating through its subsidiary, First-Citizens Bank & Trust Company. It provides comprehensive retail banking, commercial lending, leasing, and wealth management services via a nationwide branch network and digital platforms. In 2023 acquisition of Silicon Valley Bank, it also specializes in banking for tech, healthcare, and innovation firms.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.